Anavex Life Sciences Corp (AVXL)

[Steady_T]

There are several ways that the AD trial might not directly lead to approval. Even if the endpoints in the P2b/3 trial were met the FDA could want to see larger numbers than were in this trial. Also FDA could simply want to see a second P3 trial.

Anavex going for AA would alleviate both of those possible concerns by requiring a P3/4 trial of a size that makes the FDA happy while getting a treatment better than the current AD SOC available for patients.